On Oct. 12, 2021, Withings announced its ScanWatch received FDA clearance to record electrocardiogram (ECG) and oxygen saturation (Sp02) measurements for atrial fibrillation detection. It also provides sleep tracking and analysis of sleep patterns.
About ScanWatch
ScanWatch is a wearable, Bluetooth-connected wrist-worn watch. According to the company’s press release, it can help detect atrial fibrillation through ECG and blood oxygen levels through Sp02. It also performs general wellness functions like monitoring sleep cycles and physical activity and checking heart rate. It has a companion mobile app.
It features two stainless steel electrodes on the back case of the watch, which are always in contact with the skin. A third electrode is accessible on the top of the device. Additionally, the Sp02 measurements are obtained by a photoplethysmograph sensor on the back of the device.
ScanWatch provides sleep tracking and sleep pattern analysis, including length, depth and quality of sleep. Also, it can wake users up with gentle vibration at an ideal time in their sleep cycle.
The smartwatch will be available in early Nov. 2021.
Read more industry news from the AASM.
